tiprankstipranks
Advertisement
Advertisement

TRVI Stock Latest News

Trevi Therapeutics price target raised to $30 from $18 at Stifel
The FlyTrevi Therapeutics price target raised to $30 from $18 at Stifel
14d ago
TRVI
Trevi Therapeutics price target raised to $29 from $21 at Clear Street
PremiumThe Fly
Trevi Therapeutics price target raised to $29 from $21 at Clear Street
14d ago
TRVI
Trevi Therapeutics price target raised to $20 from $18 at Morgan Stanley
PremiumThe Fly
Trevi Therapeutics price target raised to $20 from $18 at Morgan Stanley
15d ago
TRVI
Trevi Therapeutics Charts Cash-Rich Path Through Key Trials
PremiumCompany Announcements
Trevi Therapeutics Charts Cash-Rich Path Through Key Trials
15d ago
TRVI
Analyst Reiterates Buy on Trevi Therapeutics, Slightly Lowers Price Target to $23 Amid Advancing Haduvio Pipeline
PremiumRatings
Analyst Reiterates Buy on Trevi Therapeutics, Slightly Lowers Price Target to $23 Amid Advancing Haduvio Pipeline
16d ago
TRVI
Unusually active option classes on open April 17th
PremiumThe FlyUnusually active option classes on open April 17th
1M ago
UBS
UMC
Trevi Therapeutics Prices Public Offering to Fund Haduvio
Premium
Company Announcements
Trevi Therapeutics Prices Public Offering to Fund Haduvio
1M ago
8K
TRVI
Trevi Therapeutics 11.6M share Spot Secondary priced at $13.00
Premium
The Fly
Trevi Therapeutics 11.6M share Spot Secondary priced at $13.00
1M ago
TRVI
Closing Bell Movers: Netflix down 9% as Q2 outlook misses, Hastings leaves board
PremiumThe Fly
Closing Bell Movers: Netflix down 9% as Q2 outlook misses, Hastings leaves board
1M ago
AA
CNS
Trevi Therapeutics announces $150M common stock offering
PremiumThe Fly
Trevi Therapeutics announces $150M common stock offering
1M ago
TRVI
Trevi Therapeutics: Positive Needham Conference Takeaways Reinforce Buy Rating and Favorable Risk‑Reward Profile
PremiumRatings
Trevi Therapeutics: Positive Needham Conference Takeaways Reinforce Buy Rating and Favorable Risk‑Reward Profile
1M ago
TRVI
Trevi Therapeutics price target lowered to $24 from $25 at JonesResearch
PremiumThe Fly
Trevi Therapeutics price target lowered to $24 from $25 at JonesResearch
2M ago
TRVI
Trevi Therapeutics Maps Phase III Path and Runway
PremiumCompany AnnouncementsTrevi Therapeutics Maps Phase III Path and Runway
2M ago
TRVI
Trevi Therapeutics price target lowered to $18 from $19 at Morgan Stanley
Premium
The Fly
Trevi Therapeutics price target lowered to $18 from $19 at Morgan Stanley
2M ago
TRVI
Trevi Therapeutics reports Q4 EPS (6c), consensus (10c)
Premium
The Fly
Trevi Therapeutics reports Q4 EPS (6c), consensus (10c)
2M ago
TRVI
Trevi Therapeutics options imply 6.8% move in share price post-earnings
PremiumThe Fly
Trevi Therapeutics options imply 6.8% move in share price post-earnings
2M ago
TRVI
TRVI Earnings this Week: How Will it Perform?
PremiumPre-Earnings
TRVI Earnings this Week: How Will it Perform?
2M ago
TRVI
Trevi Therapeutics Aligns With FDA on Phase 3 Cough Trials
PremiumCompany Announcements
Trevi Therapeutics Aligns With FDA on Phase 3 Cough Trials
2M ago
8K
TRVI
De-Risked Phase 3 Strategy and FDA Alignment Underpin Buy Rating on Trevi for Haduvio in IPF Cough
PremiumRatings
De-Risked Phase 3 Strategy and FDA Alignment Underpin Buy Rating on Trevi for Haduvio in IPF Cough
2M ago
TRVI
Trevi completes EOP2 with FDA, on track for Q2 Phase 3 initiation, says Stifel
PremiumThe FlyTrevi completes EOP2 with FDA, on track for Q2 Phase 3 initiation, says Stifel
2M ago
TRVI
Advancing Haduvio in IPF-Related Chronic Cough: FDA-Endorsed Phase 3 Path and Strong Cash Position Underscore Undervalued Multibillion-Dollar Opportunity for Trevi
Premium
Ratings
Advancing Haduvio in IPF-Related Chronic Cough: FDA-Endorsed Phase 3 Path and Strong Cash Position Underscore Undervalued Multibillion-Dollar Opportunity for Trevi
2M ago
TRVI
Trevi Therapeutics completes End-of-Phase 2 meeting with FDA
Premium
The Fly
Trevi Therapeutics completes End-of-Phase 2 meeting with FDA
2M ago
TRVI

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >